Supernus Pharmaceuticals Inc (SUPN)

Gross profit margin

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Gross profit (ttm) US$ in thousands 259,929 191,877 155,103 117,378 119,761 200,657 186,315 206,743 205,614 162,132 177,317 171,308 177,659 204,692 225,169 248,395 248,020 284,019 267,992 263,335
Revenue (ttm) US$ in thousands 661,817 654,387 632,578 598,906 607,521 619,414 641,163 674,751 673,056 651,277 618,187 585,808 560,079 545,016 551,524 536,576 506,717 465,383 418,476 402,257
Gross profit margin 39.28% 29.32% 24.52% 19.60% 19.71% 32.39% 29.06% 30.64% 30.55% 24.89% 28.68% 29.24% 31.72% 37.56% 40.83% 46.29% 48.95% 61.03% 64.04% 65.46%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $259,929K ÷ $661,817K
= 39.28%

The gross profit margin of Supernus Pharmaceuticals Inc has exhibited fluctuations over the past few years. Starting from March 31, 2020, at 65.46%, the gross profit margin has generally shown a declining trend, with occasional fluctuations. By December 31, 2024, the gross profit margin had improved to 39.28% from a low of 19.60% in March 31, 2024.

The decreasing trend in the gross profit margin indicates challenges in maintaining profitability, possibly due to factors such as increasing production costs, pricing pressures, or changes in product mix. However, the improvement in the margin by the end of 2024 suggests that the company may have implemented strategies to enhance efficiency and effectiveness in its operations.

Analyzing the gross profit margin over time allows stakeholders to assess the company's ability to generate profit from its core operations, and serves as an important indicator of operational efficiency and pricing strategies. Further monitoring and analysis of the gross profit margin will be essential for evaluating the company's financial performance and profitability in the future.